Pfizer Inc.: timeline
Every dated event on file, newest first: history, results, dividends, splits, index changes, insider trades, layoffs and recalls, each with its source.
140 events
On the market-cap history; source: Market-cap history on value.today.
Point at a marker under the line to see the event. Green: good news by its nature (a raise, an index entry), orange: bad (a cut, a layoff), grey: neither.
2026
- Nov 3, 2026Results released
Form 8-K filed 03 Nov 2026
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Sep 20262 recalls reported to Drugs (FDA)
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-; Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mc
Product recalls · source: Drugs (FDA)
- Aug 12, 20263 insiders bought $3.0 million of shares on the market
Open-market purchases between 05 Aug and 12 Aug 2026
Insider buying and large selling · source: SEC Forms 4 and 5
- Aug 4, 2026Results released
Form 8-K filed 04 Aug 2026
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Jun 28, 2026Dividend of $0.86 a share
Quarter to 28 Jun 2026; the first on file
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- May 5, 2026Results released
Form 8-K filed 05 May 2026
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Feb 26, 2026Annual report filed (Form 10-K)
For the year to 31 Dec 2025
Annual reports · source: SEC EDGAR (10-K, 20-F, 40-F)
- Feb 3, 2026Results released
Form 8-K filed 03 Feb 2026
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
2025
- Dec 31, 2025Dividend of $0.86 a share
Quarter to 31 Dec 2025; the first on file
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- Nov 4, 2025Results released
Form 8-K filed 04 Nov 2025
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Aug 5, 2025Results released
Form 8-K filed 05 Aug 2025
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Aug 4, 2025Recall: Vial Label: Epinephrine Injection, USP, 1mg/10mL (0.1 mg/mL), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 600
49,620 vials
Product recalls · source: Drugs (FDA)
- Jul 20252 recalls reported to Drugs (FDA)
Bicillin L-A (penicllin G benzathine injectable suspension),; Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-cou
Product recalls · source: Drugs (FDA)
- Jun 29, 2025Dividend of $0.86 a share
Quarter to 29 Jun 2025; the first on file
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- May 28, 2025Recall: DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, F
98,410 vials
Product recalls · source: Drugs (FDA)
- Apr 29, 2025Results released
Form 8-K filed 29 Apr 2025
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Apr 29, 2025Restructuring
A plan to exit or dispose of activities, usually with job cuts.
Notable 8-K events · source: SEC EDGAR (Form 8-K)
- Apr 4, 2025
- Feb 27, 2025Annual report filed (Form 10-K)
For the year to 31 Dec 2024
Annual reports · source: SEC EDGAR (10-K, 20-F, 40-F)
- Feb 13, 20251 insider bought $499,072 of shares on the market
Open-market purchases between 13 Feb and 13 Feb 2025
Insider buying and large selling · source: SEC Forms 4 and 5
- Feb 4, 2025Results released
Form 8-K filed 04 Feb 2025
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
2024
- Dec 31, 2024Dividend of $0.85 a share
Quarter to 31 Dec 2024; the first on file
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- Oct 30, 20241 insider bought $28,240 of shares on the market
Open-market purchases between 30 Oct and 30 Oct 2024
Insider buying and large selling · source: SEC Forms 4 and 5
- Oct 29, 2024Results released
Form 8-K filed 29 Oct 2024
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Jul 30, 2024Results released
Form 8-K filed 30 Jul 2024
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Jun 30, 2024Dividend of $0.84 a share
Quarter to 30 Jun 2024; the first on file
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- May 22, 2024Restructuring
A plan to exit or dispose of activities, usually with job cuts.
Notable 8-K events · source: SEC EDGAR (Form 8-K)
- May 22, 2024Restructuring plan: employees
Layoffs · source: SEC filing (8-K Item 2.05)
- May 20, 2024Recall: Labetalol Hydrochloride Injection, USP, 20 mg/4 mL (5 mg/mL), 4 mL Single-dose Carpuject, Sterile Cartridge Unit with Lu
220,400 cartridges
Product recalls · source: Drugs (FDA)
- May 1, 2024Results released
Form 8-K filed 01 May 2024
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Jan 30, 2024Results released
Form 8-K filed 30 Jan 2024
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
2023
- Dec 31, 2023Dividend of $0.83 a share
Quarter to 31 Dec 2023; the first on file
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- Dec 20232 recalls reported to Drugs (FDA)
Bleomycin for Injection, USP, 15 units per vial, 1 single do; 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/
Product recalls · source: Drugs (FDA)
- Dec 15, 20231 insider bought $79,410 of shares on the market
Open-market purchases between 15 Dec and 15 Dec 2023
Insider buying and large selling · source: SEC Forms 4 and 5
- Dec 15, 2023Layoff: 52 employees in South San Francisco Research Facility South San Francisco, CA
Layoff Permanent
Layoffs · source: State WARN notice
- Dec 14, 2023Results released
Form 8-K filed 14 Dec 2023
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Oct 31, 2023Results released
Form 8-K filed 31 Oct 2023
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Oct 13, 2023Results released
Form 8-K filed 13 Oct 2023
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Oct 13, 2023Restructuring plan: employees
Layoffs · source: SEC filing (8-K Item 2.05)
- Oct 2, 2023Recall: 2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector
3,200 vials
Product recalls · source: Drugs (FDA)
- Aug 1, 2023Results released
Form 8-K filed 01 Aug 2023
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Jul 2, 2023Dividend of $0.82 a share
Quarter to 02 Jul 2023; the first on file
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- May 8, 20231 insider bought $77,010 of shares on the market
Open-market purchases between 05 May and 08 May 2023
Insider buying and large selling · source: SEC Forms 4 and 5
- May 2, 2023Results released
Form 8-K filed 02 May 2023
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Mar 8, 2023Recall: MEKTOVI (binimetinib) tablets, 15 mg, 180-count bottle, Rx only, Distributed by: Array BioPharma Inc., a wholly owned su
1,926 Bottles
Product recalls · source: Drugs (FDA)
- Feb 9, 2023
- Jan 31, 2023Results released
Form 8-K filed 31 Jan 2023
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
2022
- Dec 31, 2022Dividend raised 2.5% to $0.41 a share
Quarter to 31 Dec 2022
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- Dec 20222 recalls reported to Drugs (FDA)
Vancomycin Hydrochloride for Injection, USP, 1.5 g/vial, Ste; Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/m
Product recalls · source: Drugs (FDA)
- Nov 1, 2022Results released
Form 8-K filed 01 Nov 2022
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Oct 2, 2022Dividend cut 50.0% to $0.4 a share
Quarter to 02 Oct 2022
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- Sep 27, 2022Recall: Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) 25x10 mL Single-dose vial, Rx only, Distributed by Hospira, Inc. La
103,150 10 mL vials
Product recalls · source: Drugs (FDA)
- Aug 22, 2022Recall: PROPOFOL Injectable Emulsion, 1 g/100 mL (10 mg/mL), packaged in 100 mL glass fliptop vial (NDC 0409-4699-54) further pa
5,390 vials
Product recalls · source: Drugs (FDA)
- Jul 28, 2022Results released
Form 8-K filed 28 Jul 2022
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Jul 13, 2022Recall: Propofol Injectable Emulsion, 1 g/100 mL (10 mg/mL), packaged in 100 mL per glass fliptop vial (NDC 0409-4699-54) furthe
54,000 vials
Product recalls · source: Drugs (FDA)
- Jul 3, 2022Dividend of $0.8 a share
Quarter to 03 Jul 2022; the first on file
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- May 3, 2022Results released
Form 8-K filed 03 May 2022
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Apr 22, 2022Recall: Accupril (Quinapril HCl Tablets) 10 mg, 90 Tablets Rx only NDC 0071-0530-23 Distributed by: Parke-Davis Division of Pfiz
2079 bottles
Product recalls · source: Drugs (FDA)
- Apr 20, 2022Results released
Form 8-K filed 20 Apr 2022
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Mar 21, 2022Recall: quinapril and hydrochlorothiazide tablets, 20 mg/25 mg*, 90 Tablets bottles, Rx Only, Distributed by: Greenstone, LLC, P
2442 bottles
Product recalls · source: Drugs (FDA)
- Feb 8, 2022Results released
Form 8-K filed 08 Feb 2022
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- 2022Revenue passed $100 billion
FY2022 revenue of $101.2 billion, up from $81.3 billion in FY2021.
Company history · source: Financial years
- 2022Record revenue of $101.2 billion
FY2022, the highest of the 18 years on record.
Company history · source: Financial years
- 2022Record net income of $31.4 billion
FY2022, the highest profit of the 19 years on record.
Company history · source: Financial years
Share price moves are worked out where the site has the listing's daily prices from the exchange itself: India (NSE), Taiwan (TWSE, TPEx), Brazil (B3), Poland (GPW), Russia (MOEX), Hong Kong (HKEX) and Sri Lanka (CSE). US listings have no daily price source on the site yet.
Sources: company history from Wikidata, SEC EDGAR, GLEIF and the site's own tables; results releases from SEC EDGAR (Form 8-K, item 2.02); annual reports from SEC EDGAR (10-K, 20-F, 40-F); dividend raises and cuts from SEC filings (dividends declared per share); index changes from Index providers' announcements as listed on Wikipedia; insider buying and large selling from SEC Forms 4 and 5; notable 8-k events from SEC EDGAR (Form 8-K); layoffs from State WARN notices and SEC 8-K item 2.05; product recalls from NHTSA, CPSC and FDA. Recurring events go back 15 years; the company's history is shown in full. Dividends appear when the amount per share changed; insider selling when a month's sales reach $10 million or 0.01% of the company.